Otlertuzumab

Otlertuzumab (TRU-016) is a humanized anti-CD37 monoclonal antibody that can be used for cancer research[1].

Product Specifications

CAS Number

[1372645-37-8]

Product Name Alternative

TRU-016

UNSPSC

12352203

Target

Others

Type

Inhibitory Antibodies

Related Pathways

Others

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/otlertuzumab.html

Purity

99.00

Solubility

10 mM in DMSO

Smiles

[Otlertuzumab]

Molecular Weight

(104.8093 kDa)

References & Citations

[1]Byrd JC, et al. A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia. Blood. 2014 Feb 27;123 (9) :1302-8.|[2]Baum P R, et al. Evaluation of the effect of TRU-016, an anti-CD37 directed SMIP in combination with other therapeutic drugs in models of non-Hodgkin's lymphoma. Journal of Clinical Oncology, 2009, 27 (15_suppl) : 8571-8571.|[3]Cerveny C G, et al. In vitro and in vivo anti-B cell lymphoma activities of TRU-016. Journal of Clinical Oncology, 2008, 26 (15_suppl) : 3074-3074.